Related Experiment Video
Updated: Oct 15, 2025
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma
Han Wu1,2,3, Xin-Fei Xu3, Jia-Qi Zhu1,2
1Department of Hepatobiliary, Pancreatic and Minimal Invasive Surgery, Zhejiang Provincial People's Hospital (People's Hospital of Hangzhou Medical College), Hangzhou, China.
Abstract:
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, which lacks effective inhibition of progression and metastasis in the advanced clinical stage. Mesoporous silica nanoparticle (MSN)-based cytotoxic or immunoregulatory drug-loading strategies have attracted widespread attention in the recent years. As a representative of mesoporous biomaterials, MSNs have good biological characteristics and immune activation potential and can cooperate with adjuvants against HCC. This review summarizes the possible future development of the field from the perspective of tumor immunity and aims to stimulate the exploration of the immune mechanism of MSN-based therapy. Through this point of view, we hope to develop new clinical immune drugs that can be applied to HCC clinical management in the future.
Insights
Mesoporous silica nanoparticles (MSNs) show promise for treating advanced hepatocellular carcinoma (HCC) by leveraging tumor immunity. Further research into MSN-based immunotherapies could lead to new treatments for HCC.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Cancer Immunology
Background:
- Hepatocellular carcinoma (HCC) is a major global cancer with limited treatment options for advanced stages.
- Mesoporous silica nanoparticles (MSNs) are emerging as versatile platforms for drug delivery in cancer therapy.
- MSNs possess favorable biological properties and immune-modulating potential relevant for HCC treatment.
Purpose of the Study:
- To review the potential of MSN-based therapies for hepatocellular carcinoma (HCC) from a tumor immunity perspective.
- To explore the immune mechanisms underlying MSN-based treatment strategies for HCC.
- To stimulate future research directions for developing novel immunotherapies for HCC.
Main Methods:
- Literature review focusing on mesoporous silica nanoparticles (MSNs) and their application in hepatocellular carcinoma (HCC) research.
- Analysis of current strategies involving MSN-based drug delivery (cytotoxic and immunoregulatory).
- Exploration of the interplay between MSNs, tumor immunity, and HCC progression.
Main Results:
- MSNs can be engineered for targeted drug delivery, enhancing cytotoxic effects against HCC.
- MSNs demonstrate potential in modulating the tumor microenvironment and activating anti-tumor immune responses.
- Combination of MSNs with adjuvants offers a promising strategy for synergistic effects against HCC.
Conclusions:
- Mesoporous silica nanoparticles (MSNs) represent a promising platform for developing advanced hepatocellular carcinoma (HCC) immunotherapies.
- Understanding the immune mechanisms of MSN-based therapies is crucial for optimizing clinical applications in HCC.
- Future research should focus on translating MSN-based immunomodulatory strategies into effective clinical treatments for HCC.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
08:53Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery
Published on: April 16, 2019